Immutep Ltd
Research Immutep Ltd (IMMP) on Bullrun: market cap USD 55.31M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMMP
- ExchangeNASDAQ
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 55.31M
- Financial periodQ1 2026
- Free cash flowAUD 13.51M
Valuation Snapshot
latest market cap is USD 55.31M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | n/a | n/a | -AUD 45.85M | n/a | n/a | AUD 73.89M | AUD 1.68M | AUD 172.47M |
| FY2023 | n/a | n/a | -AUD 40.81M | n/a | n/a | AUD 103.73M | AUD 1.61M | AUD 115.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 55.31M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 416.30M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 315.86M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 287.96M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 157.71M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 287.19M | n/a | n/a | n/a |
About Immutep Ltd
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immutep Ltd's market cap?
Immutep Ltd's market capitalization is USD 55.31M.
What does Immutep Ltd do?
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.